Advertisement

Topics

PubMed Journals Articles About "Eribulin Mesylate In Combination With Intermittent Erlotinib In Patients With Previously Treated, Advanced Non-Small Cell Lung Cancer" RSS

16:52 EST 22nd January 2019 | BioPortfolio

Eribulin Mesylate In Combination With Intermittent Erlotinib In Patients With Previously Treated, Advanced Non-Small Cell Lung Cancer PubMed articles on BioPortfolio. Our PubMed references draw on over 21 million records from the medical literature. Here you can see the latest Eribulin Mesylate In Combination With Intermittent Erlotinib In Patients With Previously Treated, Advanced Non-Small Cell Lung Cancer articles that have been published worldwide.

More Information about "Eribulin Mesylate In Combination With Intermittent Erlotinib In Patients With Previously Treated, Advanced Non-Small Cell Lung Cancer" on BioPortfolio

We have published hundreds of Eribulin Mesylate In Combination With Intermittent Erlotinib In Patients With Previously Treated, Advanced Non-Small Cell Lung Cancer news stories on BioPortfolio along with dozens of Eribulin Mesylate In Combination With Intermittent Erlotinib In Patients With Previously Treated, Advanced Non-Small Cell Lung Cancer Clinical Trials and PubMed Articles about Eribulin Mesylate In Combination With Intermittent Erlotinib In Patients With Previously Treated, Advanced Non-Small Cell Lung Cancer for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Eribulin Mesylate In Combination With Intermittent Erlotinib In Patients With Previously Treated, Advanced Non-Small Cell Lung Cancer Companies in our database. You can also find out about relevant Eribulin Mesylate In Combination With Intermittent Erlotinib In Patients With Previously Treated, Advanced Non-Small Cell Lung Cancer Drugs and Medications on this site too.

Showing "Eribulin Mesylate Combination With Intermittent Erlotinib Patients With" PubMed Articles 1–25 of 34,000+

Eribulin Mesylate as Third or Subsequent Line Chemotherapy for Elderly Patients with Locally Recurrent or Metastatic Breast Cancer: A Multicentric Observational Study of GIOGer (Italian Group of Geriatric Oncology)-ERIBE.

Metastatic breast cancer (MBC) is highly prevalent in middle-aged or elderly patients. Eribulin is a nontaxane microtubule inhibitor, approved for the treatment of pretreated MBC. This multicentric study (sponsored by GIOGer, Italian Group for Geriatric Oncology) was designed to assess the efficacy and tolerability of eribulin, according to parameters usually used in geriatric oncology.


Eribulin in the treatment of advanced breast cancer: real-world scenario from 39 Italian centers - ESEMPiO study.

We performed a multicenter retrospective cohort study of eribulin mesylate (EM) use in Italy, to describe the current practice for metastatic breast cancer patients (ESEMPiO) in the real-world.

Long-Term Response with Eribulin Mesylate in a Breast Cancer Patient: A Case Report.

Despite the wide pharmacological armamentarium available for the treatment of metastatic breast cancer (MBC), long-lasting control of disease is challenging, especially in heavily pretreated patients. In this case report, we documented a long-lasting complete response (CR) with eribulin in a relatively young woman with MBC and bone metastasis, who did not benefit from prior chemotherapy regimens. Besides CR, the patient was able to maintain an excellent performance status and was free from the severe pain e...


Multiple modes of action of eribulin mesylate: Emerging data and clinical implications.

Eribulin mesylate (eribulin) is a synthetic analogue of the marine-sponge natural product halichondrin B. Eribulin exhibits potent antiproliferative activities against a variety of human cancer cell types in vitro and in vivo, and is used for the treatment of certain patients with advanced breast cancer or liposarcoma who are refractory to other treatments. The antiproliferative effects of eribulin have long been attributed to its antimitotic activities. Unlike other microtubule-targeting agents, eribulin i...

Activity of Eribulin Mesylate in Brain Metastasis from Breast Cancer: A Stone in a Pond?

Brain metastases develop in approximately 10-25% of patients with metastatic breast cancer (MBC) and are associated with a very poor prognosis.

Effects of proton pump inhibitor co-administration on the plasma concentration of erlotinib in patients with non-small cell lung cancer.

Erlotinib is used for treating non-small cell lung cancer (NSCLC). Intestinal absorption of erlotinib is impaired under gastric pH elevation, therefore, co-administration of gastric acid suppressants may provide lower blood concentration of erlotinib. We investigated the effects of erlotinib co-administration with proton pump inhibitors (PPI) and histamine H2 receptor blockers (H2RB) on the plasma concentration of erlotinib and erlotinib-induced adverse reaction in NSCLC patients.

Eribulin as a Feasible and Safe Monotherapy in a Dialytic Pretreated Woman with Metastatic Breast Cancer: A Case Report.

Eribulin, a non-taxane inhibitor of microtubule dynamics, is approved for the treatment of metastatic breast cancer patients after progression with anthracyclines and taxanes. Nevertheless, to our knowledge, information on its use in dialytic patients is not available to date. This report describes the case of a chemo-pretreated dialytic woman with lung, bone, and liver metastasis from breast cancer, who experienced stable disease with a response < 20% with eribulin in fifth line after 3 hormonal lines and ...

Predictive Factors of Eribulin Activity in Metastatic Breast Cancer Patients.

Predictive factors of response to eribulin are lacking. We aimed to investigate the activity and safety of eribulin in a real-world population of metastatic breast cancer (MBC) patients and to identify possible predictive factors of progression-free survival (PFS) and objective response.

Survival outcomes in patients with non-small-cell lung cancer treated with erlotinib.

Erlotinib is used to treat non-small-cell lung cancer (NSCLC). Erlotinib was subsidized on the Pharmaceutical Benefits Schedule in Australia for the treatment of advanced stage (IIIB or IV) NSCLC (August 2008). In the pivotal trial supporting initial subsidy, erlotinib increased overall survival (OS) by 2 months compared with placebo (adjusted hazard ratio, 0.70; 95% confidence interval: 0.58-0.85). We examined the effectiveness of erlotinib in a 'real-world' setting by measuring survival outcomes in NSCLC ...

Eribulin Treatment in Patients with Liver Metastatic Breast Cancer: Eight Italian Case Reports.

Liver metastases are very common in metastatic breast cancer (MBC); current treatments for these lesions are based on systemic chemotherapy, endocrine- or human epidermal growth factor receptor 2 (HER2)-targeted therapy, and palliative therapy. However, no standard approach has been clearly identified for second and further chemotherapy lines in MBC patients. In the phase III clinical trial EMBRACE, eribulin was particularly effective in reducing liver lesions and improving both overall survival and progres...

A Pilot Phase II Study of Erlotinib for the Treatment of Patients with Relapsed/Refractory Acute Myeloid Leukemia.

Erlotinib, an epidermal growth factor receptor (EGFR) inhibitor, may have off-target activity inducing acute myeloid leukemia (AML) differentiation, possibly through SYK inhibition. We investigated erlotinib in a pilot phase II study for efficacy in relapsed/refractory AML patients at a dose of 150 mg once daily in 28-day cycles. Twenty-nine patients were treated for a median of 29 days (range 12-142 days). Seven patients (24%) received > 1 cycle of therapy and 12 (41%) discontinued treatment before day 28 ...

Eribulin in Heavily Pretreated Metastatic Breast Cancer Patients in the Real World: A Retrospective Study.

The aim of this study was to investigate efficacy and safety of eribulin in heavily pretreated patients with advanced breast cancer (BC) in a real-life setting.

A phase I study of the farnesyltransferase inhibitor Tipifarnib in combination with the epidermal growth factor tyrosine kinase inhibitor Erlotinib in patients with advanced solid tumors.

Introduction Based on preclinical cytotoxic synergy between tipifarnib and erlotinib, a phase I study of this combination was conducted in patients with advanced solid tumors to evaluate safety, tolerability, maximum tolerated dose (MTD) and preliminary evidence of efficacy. Methods Patient enrollment followed the traditional "3 + 3" dose escalation scheme, through 4 dose levels, ranging from tipifarnib 200 mg twice daily plus erlotinib 75 mg once daily to tipifarnib 300 mg twice daily plus erlotinib 150...

Promising effects of eribulin for cystic lung metastases of epithelioid sarcoma: a case report.

Epithelioid sarcoma (ES) is a rare and aggressive type of soft tissue sarcoma with resistance to systemic chemotherapy. Therefore, new treatment options are required for patients with advanced ES. Eribulin is a novel potential treatment option for patients with inoperative sarcoma. We herein report a case of a 27-year-old Japanese man with cystic lung metastases from an ES in the left forearm, resulting in long-term stable disease. A solid, metastatic sarcomatous nodule appeared in the right lung, as shown ...

First-line onartuzumab plus erlotinib treatment for patients with MET-positive and EGFR mutation-positive non-small-cell lung cancer.

The phase II JO28638 study evaluated first-line onartuzumab plus erlotinib in patients with MET-positive advanced, metastatic, or post-operative recurrent non-small-cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) mutations. The study was stopped following termination of the global METLung study (OAM4971g), which showed lack of efficacy in the onartuzumab/erlotinib arm. We present immature efficacy and safety data from JO28638.

Effect of Intermittent Compared With Continuous Energy Restricted Diet on Glycemic Control in Patients With Type 2 Diabetes: A Randomized Noninferiority Trial.

Intermittent energy restriction is an alternative weight loss method that is becoming popular; however, to date, there are no long-term clinical trials of intermittent energy restriction in patients with type 2 diabetes.

mTORC2 contributes to the metabolic reprogramming in EGFR tyrosine-kinase inhibitor resistant cells in non-small cell lung cancer.

Non-small cell lung cancer (NSCLC) patients with activating EGFR mutations are often successfully treated with EGFR tyrosine kinase inhibitor (TKI) such as erlotinib; however, treatment resistance inevitably occurs. Given tumor metabolism of glucose and therapeutic response are intimately linked, we explored the metabolic differences between isogenic erlotinib-sensitive and -resistant NSCLC cell lines. We discovered that the growth of erlotinib-resistant cells is more sensitive to glucose deprivation. Seaho...

Selecting an intermittent self-catheter: key considerations.

This article explores the factors that must be considered when assessing patients for intermittent self-catherisation (ISC). It discusses the various types of intermittent catheters and their properties. Key considerations for the health professional when making product recommendations are covered and emphasis is placed on teaching patients the ISC technique. The article also highlights what patients value in terms of product choice and the importance of ongoing support. It concludes by introducing the Gent...

Combination of Crizotinib and Osimertinib or Erlotinib Might Overcome MET-Mediated Resistance to EGFR Tyrosine Kinase Inhibitor in EGFR-Mutated Adenocarcinoma.

Clinical observation of continuous and intermittent application of lamivudine or entecavir resistance mutations in patients with chronic hepatitis B.

To observe continuous and intermittent application of lamivudine or entecavir resistance mutations in patients with chronic hepatitis B. Data of patients with active stage of chronic hepatitis B over the past 6 years were collected and analyzed retrospectively. The incidence of drug resistance mutation and related factors between patients taking LAM or ETV continuously and intermittently were compared with those taking LAM or ETV. Data comparison was performed using (2) test. Patients with HBV DNA≥10(5)...

How intermittent self-catheterisation can promote independence, quality of life and wellbeing.

Intermittent catheterisation is considered the gold standard for bladder drainage. This article describes intermittent self-catheterisation (ISC) and which patients are likely to benefit from it. Before deciding on a patient's suitability for ISC, health professionals should carry out a full assessment and ensure the patient and/or carers are taught the skills necessary to perform the procedure. ISC enables patients to be more independent because they can choose how often and where to undertake it, which en...

Pharmacodynamic analysis of eribulin safety in breast cancer patients using real-world post-marketing surveillance data.

Post-marketing surveillance is useful to collect safety data in real-world clinical settings. In this study, we firstly applied the post-marketing real-world data on a mechanistic model analysis for neutropenic profiles of eribulin in patients with recurrent or metastatic breast cancer (RBC/MBC). Demographic and safety data were collected using an active surveillance method from eribulin-treated RBC/MBC patients. Changes in neutrophil counts over time were analyzed using a mechanistic pharmacodynamic model....

Early emergence of de novo EGFR T790 M gatekeeper mutations during erlotinib treatment in PC9 non-small cell lung cancer cells.

The emergence of the T790 M gatekeeper mutation in the Epidermal Growth Factor Receptor (EGFR) gene is an important mechanism that can lead to the acquired resistance to EGFR-targeted tyrosine kinase inhibitors such as erlotinib or gefitinib. These drugs have been used in treating a subset of non-small cell lung cancer (NSCLC) patients harboring EGFR activating mutations. Here we investigated the paths leading to the acquisition of the T790 M mutation by establishing an erlotinib resistant PC9 cell mode...

Intermittent Catheterization Adherence Scale (ICAS): A new tool for the evaluation of patient adherence with clean intermittent self-catheterization.

Patients who have successfully acquired the intermittent self-catheterization (ISC) technique can be expected to use it on a long-term basis. The aim of the present study is to present a validated evaluation scale, referred to as the ICAS (Intermittent Catheterization Adherence Scale), which can be used to assess long-term patient adherence to prescribed ISC treatment.

Long-Lasting Exceptional Radiological Complete Response after Treatment with Eribulin in a Patient with Triple-Negative Breast Cancer with Liver Involvement.

We report the case of a 50-year-old woman with a triple-negative Ki67 80% breast cancer with liver metastases, who obtained a radiological long-lasting complete response after treatment with eribulin. The patient initially experienced progressive disease after a standard anthracycline/taxane-based adjuvant chemotherapy, a first-line treatment for metastatic disease with paclitaxel-bevacizumab, and a second-line maintenance treatment with bevacizumab and capecitabine. Eribulin was administered according to a...


Advertisement
Quick Search
Advertisement
Advertisement